We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
Total approvals
Agencies
Regulatory bodies
Founded
1980
No trial phase data available
No trial data available
No approval data available
- Researchers at the University of Chicago demonstrated that the Glo1 gene causally influences anxiety-like behavior through copy number variants, with more copies producing greater anxiety in mice. - The study uncovered that methylglyoxal (MG), a metabolic byproduct lowered by Glo1, rapidly reduces anxiety by directly activating GABA-A receptors on neurons — a previously unknown inhibitory mechanism. - A small molecule Glo1 inhibitor developed at the Beckman Research Institute successfully reduced anxiety-like symptoms in mice, suggesting a new therapeutic strategy distinct from traditional benzodiazepines. - The discovery links neuronal inhibitory tone to metabolic activity, opening potential avenues for treating anxiety disorders, epilepsy, and sleep disorders with greater specificity and fewer side effects.